PDCD1 and non-small cell lung carcinoma: On the other hand, Kras mutations in NSCLC are correlated with: increased PD-L1 expression in tumors, tumor mutational burden and TIL infiltration, resulting in superior response to anti-PD-L1/PD-1 treatment [54].